SG Americas Securities LLC Reduces Stock Holdings in ANI Pharmaceuticals, Inc. $ANIP

SG Americas Securities LLC lowered its stake in shares of ANI Pharmaceuticals, Inc. (NASDAQ:ANIP) by 67.4% during the 1st quarter, according to the company in its most recent filing with the SEC. The fund owned 31,348 shares of the specialty pharmaceutical company’s stock after selling 64,833 shares during the quarter. SG Americas Securities LLC’s holdings in ANI Pharmaceuticals were worth $2,411,000 at the end of the most recent quarter.

Other hedge funds and other institutional investors also recently bought and sold shares of the company. Vanguard Group Inc. boosted its stake in ANI Pharmaceuticals by 2.2% during the fourth quarter. Vanguard Group Inc. now owns 1,305,068 shares of the specialty pharmaceutical company’s stock worth $103,022,000 after buying an additional 27,598 shares during the period. State Street Corp raised its stake in shares of ANI Pharmaceuticals by 2.2% in the fourth quarter. State Street Corp now owns 727,204 shares of the specialty pharmaceutical company’s stock valued at $57,405,000 after acquiring an additional 15,496 shares during the period. UBS Group AG lifted its holdings in shares of ANI Pharmaceuticals by 45.8% in the 3rd quarter. UBS Group AG now owns 589,874 shares of the specialty pharmaceutical company’s stock worth $54,032,000 after acquiring an additional 185,172 shares during the last quarter. Tang Capital Management LLC lifted its holdings in shares of ANI Pharmaceuticals by 51.6% in the 4th quarter. Tang Capital Management LLC now owns 481,437 shares of the specialty pharmaceutical company’s stock worth $38,005,000 after acquiring an additional 163,937 shares during the last quarter. Finally, Geode Capital Management LLC boosted its stake in shares of ANI Pharmaceuticals by 4.2% during the 4th quarter. Geode Capital Management LLC now owns 477,272 shares of the specialty pharmaceutical company’s stock worth $37,682,000 after purchasing an additional 19,258 shares during the period. Hedge funds and other institutional investors own 76.05% of the company’s stock.

Wall Street Analysts Forecast Growth

Several equities analysts recently commented on the stock. Zacks Research downgraded shares of ANI Pharmaceuticals from a “strong-buy” rating to a “hold” rating in a report on Thursday, May 14th. Wall Street Zen upgraded ANI Pharmaceuticals from a “buy” rating to a “strong-buy” rating in a research report on Saturday, May 9th. Finally, Weiss Ratings raised ANI Pharmaceuticals from a “hold (c+)” rating to a “buy (b-)” rating in a research note on Tuesday, June 23rd. Six equities research analysts have rated the stock with a Buy rating and two have given a Hold rating to the company. According to data from MarketBeat.com, the stock presently has a consensus rating of “Moderate Buy” and a consensus target price of $107.33.

ANI Pharmaceuticals Trading Up 0.3%

NASDAQ ANIP opened at $83.05 on Thursday. The stock has a market cap of $1.89 billion, a PE ratio of 21.03 and a beta of 0.43. ANI Pharmaceuticals, Inc. has a 12 month low of $62.60 and a 12 month high of $99.50. The company’s 50-day moving average price is $80.77 and its 200-day moving average price is $79.35. The company has a current ratio of 3.12, a quick ratio of 2.52 and a debt-to-equity ratio of 1.06.

ANI Pharmaceuticals (NASDAQ:ANIP) last released its quarterly earnings data on Friday, May 8th. The specialty pharmaceutical company reported $2.05 earnings per share (EPS) for the quarter, beating the consensus estimate of $1.28 by $0.77. The company had revenue of $237.46 million during the quarter, compared to analysts’ expectations of $207.63 million. ANI Pharmaceuticals had a net margin of 9.98% and a return on equity of 27.51%. The firm’s quarterly revenue was up 20.5% on a year-over-year basis. During the same period in the previous year, the company earned $1.70 EPS. ANI Pharmaceuticals has set its FY 2026 guidance at 9.190-9.690 EPS. Equities research analysts forecast that ANI Pharmaceuticals, Inc. will post 8.03 earnings per share for the current year.

Insider Activity

In other ANI Pharmaceuticals news, Director Thomas Haughey sold 2,000 shares of the firm’s stock in a transaction on Monday, June 8th. The stock was sold at an average price of $80.88, for a total transaction of $161,760.00. Following the transaction, the director directly owned 38,878 shares in the company, valued at $3,144,452.64. This trade represents a 4.89% decrease in their position. The transaction was disclosed in a document filed with the SEC, which is available through the SEC website. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, SVP Thomas Andrew Rowland sold 459 shares of ANI Pharmaceuticals stock in a transaction on Tuesday, May 12th. The shares were sold at an average price of $79.21, for a total value of $36,357.39. Following the sale, the senior vice president directly owned 38,271 shares of the company’s stock, valued at approximately $3,031,445.91. This trade represents a 1.19% decrease in their ownership of the stock. The disclosure for this sale is available in the SEC filing. In the last ninety days, insiders have sold 81,866 shares of company stock valued at $6,435,733. Insiders own 8.10% of the company’s stock.

ANI Pharmaceuticals Company Profile

ANI Pharmaceuticals, Inc is a United States–based specialty pharmaceutical company focused on the development, manufacturing and commercialization of generic and branded prescription drugs. The company operates as an end-to-end provider, offering services that range from active pharmaceutical ingredient (API) production and formulation development to finished dosage form manufacturing and packaging.

ANI’s product portfolio encompasses injectable and oral therapies across several therapeutic areas, including endocrinology, oncology, pain management and respiratory care.